Celsus Therapeutics PLC CLTX plunged more than 80 percent after its lead drug candidate failed to meet the objectives of a Phase II trial
Shares of the London-based company shares traded recently at $1.10 a share, down $5.01.
Celsus said its MRX-6 cream for dermatitis didn't show progress in improving the disease in a four-week trial involving 73 children.
Chief Executive Gur Roshwalb said the company is "disappointed" and is analyzing data from the study to determine further plans.
With a market capitalization of $34.33 million, Celsus has four drugs in development based on multifunction anti-inflammatory compounds.
Products in its pipeline also include MRX-5, an orally-administered drug for inflammatory bowel disease, CFX-1 for cystic fibrosis and OPX-1 eye drops for conjunctivitis.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in